Latest Administration News

Immuron Limited has taken a significant step forward by submitting an Investigational New Drug application to the FDA for IMM-529, targeting Clostridioides difficile infection. The company aims to start Phase 2 trials in early 2026, addressing a critical unmet need in infectious disease treatment.

Dimerix’s latest PARASOL collaboration analysis reinforces proteinuria as a pivotal endpoint in their Phase 3 FSGS trial, setting the stage for FDA discussions on accelerated approval pathways.

Lindian Resources has successfully completed early development works at its Kangankunde Rare Earths Project in Malawi on time and within budget, setting the stage for mining operations to begin in early 2026. The company has also secured key mining equipment and is progressing with infrastructure and process plant preparations.

Imagion Biosystems has completed manufacturing its MagSense® HER2 imaging agent, progressing toward a Phase 2 clinical trial with strong collaborations and a recent AU$3.5 million capital raise.

Aumake Limited has launched Bio-Basic Ergothioneine, marking the debut of its innovative capital-light incubation model aimed at scaling premium health brands with minimal upfront investment.

One Click Group has locked in $1.25 million through a share placement, bringing Thorney Investment Group on board as a major shareholder and accelerating its Cash Advance product launch.

Epsilon Healthcare Limited reported a $3.25 million loss for 2024, reflecting the financial strain of voluntary administration and efforts to rebuild operations and client confidence.

Celsius Resources reports significant high-grade copper-gold drill results from its MCB Project in the Philippines, reinforcing confidence in the ongoing feasibility study update.

The U.S. FDA has lifted the clinical hold on Neurizon Therapeutics’ lead drug candidate NUZ-001, enabling its entry into a major ALS platform trial set for Q4 2025. This regulatory milestone accelerates the company’s clinical development and opens doors for broader neurodegenerative applications.

Unith Ltd reported an 18.8% increase in FY 2025 revenue to A$5.37 million alongside a significant capital raise, positioning itself for expansion in the burgeoning AI Digital Humans market.

Advance Zintek reports a robust 26.83% revenue increase in Q1 FY26, driven by strong growth across North America, Australia, and Europe, despite regulatory hurdles impacting zinc oxide sales in Australia.

Linius Technologies has addressed a late filing of a director's interest notice, attributing the delay to an administrative oversight involving a new class of securities. The company has updated its processes and will re-brief directors to ensure future compliance.